| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, ... Blood, The Journal of the American Society of Hematology 133 (15), 1652-1663, 2019 | 338 | 2019 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, ... Blood, The Journal of the American Society of Hematology 133 (17), 1876-1887, 2019 | 282 | 2019 |
| γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma MJ Pont, T Hill, GO Cole, JJ Abbott, J Kelliher, AI Salter, M Hudecek, ... Blood, The Journal of the American Society of Hematology 134 (19), 1585-1597, 2019 | 272 | 2019 |
| Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells A Cordeiro, ED Bezerra, AV Hirayama, JA Hill, QV Wu, J Voutsinas, ... Biology of Blood and Marrow Transplantation 26 (1), 26-33, 2020 | 261 | 2020 |
| High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, ... Blood, The Journal of the American Society of Hematology 134 (7), 636-640, 2019 | 165 | 2019 |
| A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer CP Rodriguez, Q Wu, J Voutsinas, JR Fromm, X Jiang, VG Pillarisetty, ... Clinical Cancer Research 26 (4), 837-845, 2020 | 141 | 2020 |
| Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy VA Chow, AK Gopal, DG Maloney, CJ Turtle, SD Smith, CS Ujjani, ... American journal of hematology 94 (8), E209, 2019 | 114 | 2019 |
| Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy J Ruark, E Mullane, N Cleary, A Cordeiro, ED Bezerra, V Wu, J Voutsinas, ... Biology of Blood and Marrow Transplantation 26 (1), 34-43, 2020 | 108 | 2020 |
| Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy SD Smith, BG Till, MS Shadman, RC Lynch, AJ Cowan, QV Wu, ... British journal of haematology 189 (6), 1119-1126, 2020 | 93 | 2020 |
| Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy M Shadman, J Gauthier, KA Hay, JM Voutsinas, F Milano, A Li, ... Blood advances 3 (20), 3062-3069, 2019 | 88 | 2019 |
| Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy KR Juluri, QV Wu, J Voutsinas, J Hou, AV Hirayama, E Mullane, N Miles, ... Blood Advances 6 (7), 2055-2068, 2022 | 83 | 2022 |
| Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci SS Wang, CM Vajdic, MS Linet, SL Slager, J Voutsinas, A Nieters, ... American journal of epidemiology 181 (6), 406-421, 2015 | 69 | 2015 |
| The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis PS Godavarthy, R Kumar, SC Herkt, RS Pereira, N Hayduk, ... Haematologica 105 (1), 136, 2020 | 53 | 2020 |
| Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors A Balakrishnan, A Rajan, AI Salter, PL Kosasih, Q Wu, J Voutsinas, ... Clinical Cancer Research 25 (24), 7506-7516, 2019 | 48 | 2019 |
| Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk of colorectal adenoma in a multiethnic population J Voutsinas, LR Wilkens, A Franke, TM Vogt, LA Yokochi, R Decker, ... Gut 62 (3), 416-422, 2013 | 48 | 2013 |
| Naive T-cell depletion to prevent chronic graft-versus-host disease M Bleakley, A Sehgal, S Seropian, MA Biernacki, EF Krakow, A Dahlberg, ... Journal of Clinical Oncology 40 (11), 1174, 2022 | 44 | 2022 |
| HLA class I and II diversity contributes to the etiologic heterogeneity of non-Hodgkin lymphoma subtypes SS Wang, M Carrington, SI Berndt, SL Slager, PM Bracci, J Voutsinas, ... Cancer research 78 (14), 4086-4096, 2018 | 42 | 2018 |
| Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic leukemia remission confers a leukemia-free survival advantage C Summers, QV Wu, C Annesley, M Bleakley, A Dahlberg, ... Transplantation and Cellular Therapy 28 (1), 21-29, 2022 | 41 | 2022 |
| Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre … RC Lynch, RD Cassaday, SD Smith, JR Fromm, AJ Cowan, EH Warren, ... The Lancet Haematology 8 (8), e562-e571, 2021 | 38 | 2021 |
| Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML) UH Acharya, AB Halpern, Q Wu, JM Voutsinas, RB Walter, S Yun, ... Journal of drug assessment 7 (1), 51-53, 2018 | 37 | 2018 |
